In a prospective multicenter Phase II study, maintenance therapy with bevacizumab (5 mg/kg every 3 weeks) showed promising efficacy in preserving hearing and stabilizing tumor growth over 18 months in individuals with NF2-related SWN and hearing loss due to VSs. Here, NF2 is linked to neoplasm.